Roth Capital Reaffirms Buy Rating for Biosig Technologies (BSGM)

Roth Capital restated their buy rating on shares of Biosig Technologies (NYSE:BSGM) in a research note issued to investors on Thursday morning.

Shares of NYSE BSGM traded down $0.09 during midday trading on Thursday, reaching $3.92. The company’s stock had a trading volume of 21,572 shares.

Biosig Technologies Company Profile

BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.

Featured Story: What is Net Asset Value (NAV)?

Receive News & Ratings for Biosig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply